About Kura Oncology Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.kuraoncology.com/
Frequently Asked Questions
What is the 52-week range for KURA?
The 52-week high is $13.9 and the 52-week low is $7.358.
What is the P/E ratio for KURA?
The P/E ratio data is currently unavailable.
What is the dividend yield for KURA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -207.18%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -384.30%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.19.
Analyst Recommendation Trends
Wall Street analyst consensus for KURA over the last few months:
Latest KURA News
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option P
This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.
Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors
Board additions bring diabetes-development and company-building expertise as Caspian prepares KO-7246 for advancement into clinical testingSAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”), a biotechnology company developing menin inhibitors for diabetes and other cardiometabolic diseases, today announced the appointments of Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to its Board of Directors. Caspian recently launched with $50 million in financing to advan
JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30
JP Morgan analyst Priyanka Grover initiates coverage on Kura Oncology (NASDAQ:KURA) with a Overweight rating and announces Price Target of $30.
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
– KO-7246 regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models – – KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of action, evidenced by post-treatment durability and combination benefit with semaglutide – – Findings highlight a potentially disease-modifying approach designed to restore the body’s own endogenous insulin-producing capacity – – Caspian is building a leadership position in menin-direct
Caspian Therapeutics And Kura Oncology Released Comprehensive Preclinical Data Supporting KO-7246 For Diabetes
Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura"))) today announced comprehensive preclinical data supporting KO-7246 as a potential best-in-class menin inhibitor for
Kura Oncology Q2 2026 Earnings Call Transcript
On Wednesday, Kura Oncology (NASDAQ:KURA) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kura Oncology, Inc. (KURA) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 7:45 AM EDTCompany ParticipantsTroy Wilson - Chairman,...
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni
Kura spins diabetes work into a Lilly-backed biotech startup
Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Ms. Fulk will join Kura’s senior leade
Kura Oncology Appoints Jennifer Fulk As CFO, Effective September 8
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-29 | FORD KATHLEEN | -3,668 | $10.7516 | $39,437 |
| 2026-09-29 | Leoni Mollie | -28,802 | $10.7481 | $309,567 |
| 2026-09-29 | Powl Brian T. | -15,430 | $10.7487 | $165,852 |
| 2026-09-28 | Bair Teresa Brophy | -8,442 | $10.4973 | $88,618 |
| 2026-09-28 | FORD KATHLEEN | -6,906 | $10.4973 | $72,494 |
| 2026-09-28 | Leoni Mollie | -12,448 | $10.4973 | $130,670 |
| 2026-09-28 | DOYLE THOMAS JAMES | -4,607 | $10.4972 | $48,361 |
| 2026-09-28 | Powl Brian T. | -8,000 | $10.5622 | $84,498 |
| 2026-09-28 | Powl Brian T. | -9,020 | $10.4973 | $94,686 |
| 2026-09-24 | Burrows Francis | -30,000 | - | - |
| 2026-09-24 | Burrows Francis | -20,726 | $10.8325 | $224,514 |
| 2026-09-24 | Burrows Francis | +30,000 | $6.15 | $184,500 |
| 2026-09-08 | Fulk Jennifer | +450,000 | - | - |
| 2026-08-24 | WILSON TROY EDWARD | +100,000 | $12.39 | $1,239,000 |
| 2026-08-21 | Powl Brian T. | -4,345 | $11.8903 | $51,663 |
| 2026-08-19 | Bair Teresa Brophy | -31,487 | $12.63 | $397,681 |
| 2026-08-17 | WILSON TROY EDWARD | +100,000 | $11.12 | $1,112,000 |
| 2026-06-18 | Leoni Mollie | -84,929 | $9.8233 | $834,283 |
| 2026-06-04 | Parks Diane L. | +35,000 | - | - |
| 2026-06-04 | VASCONCELLES MICHAEL | +35,000 | - | - |
| 2026-06-04 | Collins Helen Louise | +35,000 | - | - |
| 2026-06-04 | Szela Mary T | +35,000 | - | - |
| 2026-06-04 | Malley Thomas | +35,000 | - | - |
| 2026-06-04 | Hasnain Faheem | +35,000 | - | - |
| 2026-06-04 | SCHAFER CAROL | +35,000 | - | - |
| 2026-05-21 | Powl Brian T. | -10,000 | $11 | $110,000 |
| 2026-05-19 | FORD KATHLEEN | -2,257 | $9.0752 | $20,483 |
| 2026-05-19 | Powl Brian T. | -339 | $9.21 | $3,122 |
| 2026-05-18 | Bair Teresa Brophy | -2,256 | $9.3795 | $21,160 |
| 2026-03-23 | WILSON TROY EDWARD | +6,103 | - | - |
| 2026-03-23 | WILSON TROY EDWARD | +6,103 | $6.15 | $37,533 |
| 2026-03-18 | Malley Thomas | +10,000 | - | - |
| 2026-03-18 | Malley Thomas | +10,000 | $3.12 | $31,200 |
| 2026-01-27 | Burrows Francis | -1,311 | $8.4607 | $11,092 |
| 2026-01-27 | Powl Brian T. | -1,572 | $8.4607 | $13,300 |
| 2026-01-27 | Powl Brian T. | -4,842 | $8.4606 | $40,966 |
| 2026-01-27 | FORD KATHLEEN | -1,813 | $8.4607 | $15,339 |
| 2026-01-27 | Leoni Mollie | -1,341 | $8.4607 | $11,346 |
| 2026-01-27 | Leoni Mollie | -951 | $8.4607 | $8,046 |
| 2026-01-27 | Leoni Mollie | -2,233 | $8.4607 | $18,893 |
| 2026-01-27 | Leoni Mollie | -3,655 | $8.4607 | $30,924 |
| 2026-01-27 | DOYLE THOMAS JAMES | -881 | $8.4607 | $7,454 |
| 2026-01-27 | DOYLE THOMAS JAMES | -2,226 | $8.4607 | $18,834 |
| 2026-01-27 | DOYLE THOMAS JAMES | -695 | $8.4607 | $5,880 |
| 2026-01-27 | DOYLE THOMAS JAMES | -1,114 | $8.4607 | $9,425 |
| 2026-01-27 | DOYLE THOMAS JAMES | -2,226 | $8.4607 | $18,834 |
| 2026-01-27 | Bair Teresa Brophy | -4,777 | $8.4607 | $40,417 |
| 2026-01-27 | Bair Teresa Brophy | -2,335 | $8.4607 | $19,756 |
| 2026-01-27 | Bair Teresa Brophy | -4,096 | $8.4607 | $34,655 |
| 2026-01-02 | WILSON TROY EDWARD | +1,120,000 | - | - |
| 2026-01-02 | Leoni Mollie | +100,000 | - | - |
| 2026-01-02 | Leoni Mollie | +50,000 | - | - |
| 2026-01-02 | DOYLE THOMAS JAMES | +42,500 | - | - |
| 2026-01-02 | DOYLE THOMAS JAMES | +21,250 | - | - |
| 2026-01-02 | FORD KATHLEEN | +100,000 | - | - |
| 2026-01-02 | FORD KATHLEEN | +50,000 | - | - |
| 2026-01-02 | Burrows Francis | +185,000 | - | - |
| 2026-01-02 | Powl Brian T. | +100,000 | - | - |
| 2026-01-02 | Powl Brian T. | +50,000 | - | - |
| 2026-01-02 | Bair Teresa Brophy | +100,000 | - | - |
| 2026-01-02 | Bair Teresa Brophy | +50,000 | - | - |
| 2025-12-18 | Burrows Francis | -35,000 | - | - |
| 2025-12-18 | Burrows Francis | -23,726 | $9.7754 | $231,931 |
| 2025-12-18 | Burrows Francis | +35,000 | $4.8 | $168,000 |
| 2025-12-09 | Hasnain Faheem | -10,000 | $10.9764 | $109,764 |
| 2025-12-09 | Hasnain Faheem | +10,000 | $3.12 | $31,200 |
| 2025-11-14 | Bair Teresa Brophy | -8,804 | $11.1769 | $98,401 |
| 2025-11-14 | Powl Brian T. | -8,887 | $11.1769 | $99,329 |
| 2025-11-14 | Leoni Mollie | -15,485 | $11.1769 | $173,074 |
| 2025-11-14 | DOYLE THOMAS JAMES | -4,539 | $11.1769 | $50,732 |
| 2025-11-14 | FORD KATHLEEN | -6,902 | $11.1769 | $77,143 |
| 2025-11-13 | Bair Teresa Brophy | +48,900 | - | - |
| 2025-11-13 | WILSON TROY EDWARD | +182,500 | - | - |
| 2025-11-13 | Powl Brian T. | +48,900 | - | - |
| 2025-11-13 | Leoni Mollie | +82,500 | - | - |
| 2025-11-13 | DOYLE THOMAS JAMES | +24,967 | - | - |
| 2025-11-13 | FORD KATHLEEN | +48,900 | - | - |